Musaffa Logo
O
Osprey Solana Trust OSOL
$2.28 $0.03 (1.35%) 1D

Last Updated: Jul 15, 12:00 AM·OOTC

Pricing for US stocks is delayed by 24 hours

OSOL Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Osprey Solana Trust is classified as doubtful.

DOUBTFUL

Report Source: undefined Quarter Report

O

Osprey Solana Trust. Stock Analysis OSOL

United States N/A Nano Cap

Osprey Solana Trust (OSOL) Chart

Financial Metrics & Statements of Osprey Solana Trust (OSOL)

FAQ's for Osprey Solana Trust (OSOL)

  • As of August 2026, Osprey Solana Trust OSOL is classified as doubtful according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Osprey Solana Trust using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Osprey Solana Trust if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Osprey Solana Trust by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Osprey Solana Trust may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Osprey Solana Trust on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.